<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940317-0-00039</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> DATES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Effective April 18, 1994; written comments, notice of participation, and requests for a hearing by April 18, 1994; data, information, and analyses to justify a hearing by May 16, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> <!-- PJG STAG 4700 -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 -->  <USBUREAU>Food and Drug Administration</USBUREAU> <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 -->  <CFRNO>21 CFR Part 442</CFRNO> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=41 g=1 f=1 -->  <RINDOCK>[Docket No. 93N&hyph;0431]</RINDOCK> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 --> Antibiotic Drugs; Cefmetazole and Cefmetazole Sodium Injection <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Food and Drug Administration, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Final rule. <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The Food and Drug Administration (FDA) is amending the antibiotic drug regulations to provide for the inclusion of accepted standards for a new bulk form of cefmetazole and for its use in a new dosage form of cefmetazole sodium, cefmetazole sodium injection. The manufacturer has supplied sufficient data and information to establish its safety and efficacy. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> DATES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Effective April 18, 1994; written comments, notice of participation, and requests for a hearing by April 18, 1994; data, information, and analyses to justify a hearing by May 16, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </DATE> <ADDRESS> <!-- PJG ITAG l=10 g=1 f=2 --> ADDRESSES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Submit written comments to the Dockets Management Branch (HFA&hyph;305), Food and Drug Administration, rm. 1&hyph;23, 12420 Parklawn Dr., Rockville, MD 20857. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </ADDRESS> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Peter A. Dionne, Center for Drug Evaluation and Research (HFD&hyph;520), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301&hyph;443&hyph;0335. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> FDA has evaluated data submitted in accordance with regulations promulgated under section 507 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 357), as amended, with respect to a request for approval of (1) a new bulk form of cefmetazole, and (2) for its use in a new dosage form of cefmetazole sodium, cefmetazole sodium injection. The agency has concluded that the data supplied by the manufacturer concerning this antibiotic drug are adequate to establish its safety and efficacy when used as directed in the labeling and that the regulations should be amended in 21 CFR part 442 to provide for the inclusion of accepted standards for this product. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Environmental Impact <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The agency has determined under 21 CFR 25.24(c)(6) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> Submitting Comments and Filing Objections <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> This final rule announces standards that FDA has accepted in a request for approval of an antibiotic drug. Because this final rule is not controversial and because, when effective, it provides notice of accepted standards, FDA finds that notice and comment procedure is unnecessary and not in the public interest. This final rule, therefore, is effective April 18, 1994. However, interested persons may, on or before April 18, 1994, submit written comments to the Dockets Management Branch (address above). Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday. <!-- PJG 0012 frnewline --> Any person who will be adversely affected by this final rule may file objections to it and request a hearing. Reasonable grounds for the hearing must be shown. Any person who decides to seek a hearing must file (1) on or before April 18, 1994, a written notice of participation and request for a hearing, and (2) on or before May 16, 1994, the data, information, and analyses on which the person relies to justify a hearing, as specified in 21 CFR 314.300. A request for a hearing may not rest upon mere allegations or denials, but must set forth specific facts showing that there is a genuine and substantial issue of fact that requires a hearing. If it conclusively appears from the face of the data, information, and factual analyses in the request for a hearing that no genuine and substantial issue of fact precludes the action taken by this order, or if a request for a hearing is not made in the required format or with the required analyses, the Commissioner of Food and Drugs will enter summary judgment against the person(s) who request(s) the hearing, making findings and conclusions and denying a hearing. All submissions must be filed in three copies, identified with the docket number appearing in the heading of this document and filed with the Dockets Management Branch. <!-- PJG 0012 frnewline --> The procedures and requirements governing this order, a notice of participation and request for a hearing, a submission of data, information, and analyses to justify a hearing, other comments, and grant or denial of a hearing are contained in 21 CFR 314.300. <!-- PJG 0012 frnewline --> All submissions under this order, except for data and information prohibited from public disclosure under 21 U.S.C. 331(j) or 18 U.S.C. 1905, may be seen in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> List of Subjects in 21 CFR Part 442 <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Antibiotics. <!-- PJG 0012 frnewline --> Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR part 442 is amended as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 --> PART 442_CEPHA ANTIBIOTIC DRUGS <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 1. The authority citation for 21 CFR part 442 continues to read as follows: <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=4 --> Authority:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> Sec. 507 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 357). <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 2. Section 442.69 is added to subpart A to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;442.69  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Cefmetazole. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Requirements for certification <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Standards of identity, strength, quality, and purity <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Cefmetazole is (6 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> R <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ,7 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> )-7-[2-[(cyanomethyl)thio]acetamido]-7-methoxy-3-[[(1-methyl-1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> H <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> -tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid. It is so purified and dried that: <!-- PJG 0012 frnewline --> (i) Its potency is not less than 970 micrograms of cefmetazole activity per milligram. <!-- PJG 0012 frnewline --> (ii) Its moisture content is not more than 0.5 percent. <!-- PJG 0012 frnewline --> (iii) It gives a positive identity test for cefmetazole. <!-- PJG 0012 frnewline --> (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Labeling <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . It shall be labeled in accordance with the requirements of &sect;432.5 of this chapter. <!-- PJG 0012 frnewline --> (3)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Requests for certification; samples <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . In addition to complying with the requirements of &sect;431.1 of this chapter, each such request shall contain: <!-- PJG 0012 frnewline --> (i) Results of tests and assays on the batch for potency, moisture, and identity. <!-- PJG 0012 frnewline --> (ii) Samples, if required by the Director, Center for Drug Evaluation and Research: 10 packages each containing approximately 500 milligrams. <!-- PJG 0012 frnewline --> (b)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Tests and methods of assay <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Potency <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;442.70a(b)(1). <!-- PJG 0012 frnewline --> (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Moisture <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;436.201 of this chapter. <!-- PJG 0012 frnewline --> (3)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Identity <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;436.211 of this chapter using a mineral oil mull prepared as described in paragraph (b)(2) of that section. <!-- PJG 0012 frnewline --> 3. New &sect;442.270 is added to subpart C to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;442.270  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Cefmetazole injectable dosage forms. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 4. New &sect;442.270b is added to subpart C to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;442.270b  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Cefmetazole sodium injection. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (a)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Requirements for certification <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Standards of identity, strength, quality, and purity <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Cefmetazole sodium injection is a frozen, aqueous, iso-osmotic solution of cefmetazole and sodium citrate. It contains one or more suitable and harmless buffer substances and a tonicity adjusting agent. Each milliliter contains cefmetazole sodium equivalent to 20 milligrams or 40 milligrams of cefmetazole per milliliter. Its cefmetazole content is satisfactory if it is not less than 90 percent and not more than 120 percent of the number of milligrams of cefmetazole that it is represented to contain. It is sterile. It contains not more than 0.2 endotoxin units per milligram. Its pH is not less than 4.2 and not more than 6.2. It passes the identity test. The cefmetazole used conforms to the standards prescribed by &sect;442.69(a)(1). <!-- PJG 0012 frnewline --> (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Labeling <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . It shall be labeled in accordance with the requirements of &sect;432.5 of this chapter. <!-- PJG 0012 frnewline --> (3)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Requests for certification; samples <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . In addition to complying with the requirements of &sect;431.1 of this chapter, each such request shall contain: <!-- PJG 0012 frnewline --> (i) Results of tests and assays on: <!-- PJG 0012 frnewline --> (A) The cefmetazole used in making the batch for potency, moisture, and identity. <!-- PJG 0012 frnewline --> (B) The batch for potency, sterility, bacterial endotoxins, pH, and identity. <!-- PJG 0012 frnewline --> (ii) Samples, if required by the Director, Center for Drug Evaluation and Research: <!-- PJG 0012 frnewline --> (A) The cefmetazole used in making the batch: 10 packages, each containing approximately 500 milligrams. <!-- PJG 0012 frnewline --> (B) The batch: <!-- PJG 0012 frnewline --> ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) For all tests except sterility: A minimum of 12 immediate containers. <!-- PJG 0012 frnewline --> ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) For sterility testing: 20 immediate containers, collected at regular intervals throughout each filling operation. <!-- PJG 0012 frnewline --> (b)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Tests and methods of assay <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Thaw the sample as directed in the labeling. The sample solution used for testing must be at room temperature. <!-- PJG 0012 frnewline --> (1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Cefmetazole potency <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;442.70a(b)(1), except prepare the sample solution and calculate the cefmetazole content as follows: <!-- PJG 0012 frnewline --> (i)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Preparation of sample solution <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Using a suitable hypodermic needle and syringe, remove an accurately measured portion from each container immediately after thawing and reaching room temperature and dilute with mobile phase to obtain a solution containing 500 micrograms of cefmetazole per milliliter (estimated). Prepare the sample solution just prior to its introduction into the chromatograph. <!-- PJG 0012 frnewline --> (ii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Calculation <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Calculate the milligrams of cefmetazole per milliliter of sample as follows: <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <TABLE>  <!-- PJG tableformat 3,L1(0,0,0),b1,tp0,p9,9/1,g1,t1,s20,2,12 -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=95 g=1 f=1 --> &blank; <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Milligrams of cefmetazole per milliliter <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1= <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=4 --> U <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  X  <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> P <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=4 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  X  <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> d <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=5 f=4 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=95 g=1 f=1 -->  X 1,000 <!-- PJG 007 0152 intable -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=22 g=1 f=1 --> &blank; <!-- PJG /ITAG -->  </TABLE>  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=26 g=1 f=1 --> where: <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=26 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> U <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Area of the cefmetazole peak in the chromatogram of the  <!-- PJG 0011 horztab -->  sample (at a retention time equal to that observed for the standard); <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> A <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Area of the cefmetazole peak in the chromatogram of the  <!-- PJG 0012 frnewline --> cefmetazole working standard; <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> P <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=5 f=4 --> S <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Cefmetazole activity in the cefmetazole working standard  <!-- PJG 0012 frnewline --> solution in micrograms per milliliter; and <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=3 --> d <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 -->  = Dilution factor of the sample. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Sterility <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;436.20 of this chapter, using the method described in paragraph (e)(1) of that section. <!-- PJG 0012 frnewline --> (3)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Bacterial endotoxins <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in the United States Pharmacopeia bacterial endotoxins test. <!-- PJG 0012 frnewline --> (4)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> pH <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Proceed as directed in &sect;436.202 of this chapter, using the undiluted solution. <!-- PJG 0012 frnewline --> (5)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Identity <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The high-performance liquid chromatogram of the sample determined as directed in paragraph (b)(1) of this section compares qualitatively to that of the cefmetazole working standard. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: March 9, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Raymond E. Hamilton, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Acting Director, Office of Compliance, Center for Drug Evaulation and Research. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;6224 Filed 3&hyph;16&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG /STAG --></p>
		</main>
</body></html>
            